UPC Analytics
DEEN
Übersicht · Eingereicht: 13. Mai 2024

UPC_CFI_146/2024

NOVEL ANTITUMORAL USE OF CABAZITAXEL

VerletzungHauptverletzungsklageMunich LDInfringementCase Closed
ÜbersichtEntscheidungenBegründungZitateDokumenteZeitverlauf
Abdeckung: Teilweise.Begründung teilweise extrahiert — einige Abschnitte können unvollständig sein.
Zusammenfassung in einfacher Sprache

Sanofi (and related entities) brought infringement actions against STADA, Dr. Reddy's, and Zentiva entities based on EP 2 493 466, a patent covering the antitumoral use of cabazitaxel (Jevtana) in patients pretreated with docetaxel. The Munich Local Division found the patent invalid in its entirety (claims 1-9) for lack of inventive step, the NHSC regulatory document disclosing all essential features of claim 1 without any distinct technical effect being established for the dependent claims; Sanofi filed no amendment requests, and the infringement actions were dismissed with costs against Sanofi.

Angenommene Argumente
Was das Gericht akzeptiert hat — nach Partei.

  • Cabazitaxel patent EP 2 493 466 lacks inventive step over the prior art (NHSC document disclosing cabazitaxel's antitumour use in docetaxel-pretreated patients)

    BeklagterRechtsgrundlage: Art. 56 EPC; problem-solution approach

    Hinweis: Court found that the NHSC document disclosed the claimed antitumoral use of cabazitaxel, and that the skilled person would have expected this use without inventive step; no distinct technical effect was established for dependent claims relating to solvate form, dosing, or patient selection.

  • Dependent claims 3-4 (acetone solvate) lack inventive step as providing a specific solvate is common general knowledge

    BeklagterRechtsgrundlage: Art. 56 EPC

    Hinweis: Court accepted that the acetone solvate form features were not linked to a technical effect and are within common general knowledge.

  • Claims 5-7 (cabazitaxel/prednisone doses and 3-week interval) disclosed in the NHSC document

    BeklagterRechtsgrundlage: Art. 56 EPC

    Hinweis: Court accepted that dose and interval claims were disclosed in the NHSC document.

  • Claim 9 (prior docetaxel dose of at least 225 mg/m²) does not provide a distinct technical effect

    BeklagterRechtsgrundlage: Art. 56 EPC

    Hinweis: Court found the 225 mg/m² limitation to be arbitrary or to respond to the same technical problem without a distinct technical effect.

Zurückgewiesene Argumente
Was das Gericht nicht akzeptiert hat — und warum.

  • EP 2 493 466 (cabazitaxel antitumour use patent) is valid over the prior art

    KlägerRechtsgrundlage: Art. 56 EPC

    Begründung: Court found claims 1-9 invalid for lack of inventive step based on the NHSC document as closest prior art; no distinct technical effect established for any dependent claim feature.

  • No auxiliary requests for patent amendment filed

    KlägerRechtsgrundlage: R. 30 RoP

    Begründung: Sanofi did not file a R. 30 RoP application for patent amendment; therefore no auxiliary requests were available to consider.

Zentrale Rechtsgrundsätze
In der Begründung herangezogene Doktrinen und Regeln.
Problem-solution approach applied to pharmaceutical second medical use: prior art disclosure of use negates inventive step absent distinct technical effectSpecific solvate forms within common general knowledge do not establish inventive step without a linked technical effectArbitrary limitations or limitations responding to the same problem without distinct technical effect do not confer inventive stepWhere patent is invalid in its entirety, infringement actions are dismissedPatentee that fails to file R. 30 RoP amendment request has no auxiliary requests to consider

Weitere Fälle zu diesem Grundsatz ansehen.

Herangezogener Stand der Technik
Zitierte Schriften und die Rolle, die sie gespielt haben.
  • NHSC document (clinical/regulatory document disclosing cabazitaxel antitumour use in docetaxel-pretreated patients)Neuheitsschädlich